Persistent evidence tracking for precision medicine. Each board accumulates drug candidates, hypotheses, and claims — scored by freshness, clinical evidence, and contradiction signals.
Active BoardsExponential Decay ScoringContradiction AlertsLive from Database
⚗ Prediction Spotlight — KRAS G12C Subgroup (~1-2% of PDAC)
Adagrasib — KRAS G12C covalent inhibitor
GaiaLab surfaces adagrasib for KRAS-mutant panels. FDA approved December 2022 for KRAS G12C NSCLC. Repurposing signal for the ~1-2% of PDAC patients with G12C.
Key Trial
NCT03785249 — KRYSTAL-1, Phase 1/2 (active, not recruiting)
G12D gap (90% of PDAC)
IMM-1-104 NCT05585320 — Phase 1/2a active; no G12D inhibitor currently FDA approved
Critical caveat: Adagrasib and sotorasib target KRAS G12C — a mutation present in only ~1-2% of PDAC. The dominant mutation is G12D (~90%), which no approved drug directly inhibits.
KRAS G12D — no approved inhibitor: G12D is present in ~90% of PDAC but lacks a reactive cysteine at position 12, making covalent targeting impossible. Non-covalent and bifunctional degrader strategies are in Phase 1 — the first G12D-specific trial (MRTX1133, NCT05737706) was terminated.
SMAD4 loss — no targeted therapy: SMAD4 loss (~55% of PDAC) predicts resistance to standard chemotherapy and immune checkpoint therapy via stromal activation, but no approved drug exploits or reverses this vulnerability.
BRCA2 + PARP inhibitors in PDAC vs. ovarian: Whether the POLO trial benefit (olaparib maintenance) translates to the same degree as in BRCA2-mutant ovarian cancer is still being established — the desmoplastic PDAC microenvironment creates unique drug delivery and immune barriers not present in ovarian tumors.
📡 LassaAI Outbreak Forecast
All 37 Nigerian States: LOW Risk (Wet Season)
Forecast from the LassaAI national model (XGBoost; AUROC 0.880 vs 0.849 naive baseline on a 2024 out-of-time hold-out — a modest, seasonality-driven gain, not a breakthrough). The per-state view below is illustrative; the validated model is national. Preprint. High-risk season: November through April.
Favipiravir vs. ribavirin in humans: Favipiravir shows superior efficacy in NHP models but no completed Phase 2/3 RCT in human Lassa fever has been published as of 2026. Whether NHP advantage translates to human outcomes is the central open question.
Ribavirin resistance: No systematic sequencing of LASV from ribavirin treatment failures has been published. L polymerase resistance variants analogous to those in HCV and influenza have not been characterised in field isolates.
Pregnancy management: CFR in Lassa fever complicating pregnancy exceeds 60%. Favipiravir and molnupiravir carry teratogenicity concerns — no treatment trial has enrolled pregnant patients. Evidence-based guidance for this highest-risk group is absent.
APOE4/4 subgroup: Whether lecanemab slows cognitive decline in APOE4 homozygotes is under active study — this highest-risk genotype was underrepresented in CLARITY AD and had elevated ARIA risk.
TREM2 causal pathway: The relationship between TREM2 variants and amyloid clearance is associative in population studies — not experimentally confirmed as causal in human models.
PSEN1/2 familial vs. sporadic: Early-onset familial AD driven by PSEN1/PSEN2 mutations may respond differently to anti-amyloid therapies than sporadic late-onset AD — the panel does not distinguish these subtypes.